REGEN Line from Lira Clinical. Introducing A New Era of Skin Renewal, bringing advanced salmon-derived biotechnology into regenerative skincare and redefining what clinical results can look like.
Lira Clinical’s 98% brightening philosophy has always been the foundation of our clinically proven results. Building on this legacy, we are introducing Clinical Brightening, an evolution of our approach that enhances brightening benefits with regenerative support, including improved hydration, circulation, and firming.
This Is Where Lira Clinical’s Latest Innovation Begins
At the center of this advancement is a first-of-its-kind ingredient combination: PDRN, Wild Salmon Stem Cell-CM (Marine Cellular Complex), and Copper Tripeptide-1. The REGEN Line is the first in the clinical market to bring these three technologies together, creating a multi-pathway approach to regeneration that goes beyond anything previously available.
PDRN, a DNA-derived compound from salmon, is widely recognized for its ability to support tissue repair, stimulate collagen production, and promote skin regeneration. However, on its own, its regenerative potential is limited to a single pathway.
By combining PDRN with Wild Salmon Stem Cell-CM, rich in proteins, growth factors, and signaling molecules that drive cellular communication, Lira Clinical significantly amplifies this regenerative effect. The addition of Copper Tripeptide-1 further enhances collagen production, supports skin firmness, and reinforces structural integrity.
Together, this exclusive combination delivers up to 4x more regenerative power than PDRN alone, enabling a more complete and coordinated skin response.
Rather than targeting one function, this technology works across multiple regenerative pathways simultaneously: supporting cellular repair, improving communication between cells, and rebuilding skin structure from within. The result is not just treated skin, but skin that is actively restored.
This multi-pathway regeneration directly supports the three core drivers behind what Lira Clinical defines as Clinical Brightening: hydration, circulation, and firmness. As these improve, brightness becomes a visible, measurable result of healthier, more resilient skin, not a temporary surface correction.
The Outcome is Skin That Appears More Revitalized, Even-Toned, and Structurally Supported Over Time
This innovation will be a key focus at Purely Clinical 3.0, Global Skin Affair Tour in San Francisco, where skincare professionals will have the rare opportunity to learn directly from the scientists and experts behind this technology. Attending the event from Wildtype are Justin Kolbeck, Co-Founder & CEO; Dr. Aryé Elfenbein, Co-Founder; Larry Weiss, MD, Product Developer of Wildtype and Managing Partner of BiomeMimetics, LLC; and Taeryn Kim, Specialist in Cellularized Materials and Tissue Engineering.
Together, this group brings deep expertise across biotechnology, regenerative medicine, and tissue engineering, offering attendees a unique, behind-the-scenes look at how this innovation is shaping the future of regenerative skincare.
The REGEN Line
For professionals, this represents more than a new ingredient; it introduces a new capability. By delivering 4x more regenerative power than traditional PDRN alone, and combining three advanced technologies in one system, the REGEN Line allows practitioners to move beyond surface correction and begin addressing skin concerns at their source.
Lira Clinical has always built its innovations by looking beyond traditional cosmetic science, identifying breakthroughs in broader fields of biology and translating them into clinical skincare solutions. From early discoveries like the “tears of Chios” to today’s advancements in biotechnology, that philosophy remains unchanged.
With the introduction of the REGEN Line, Lira Clinical is once again setting a new standard, where clinical brightening begins not at the surface, but from within.
